GLPwatch
Saxenda for Alcohol use disorder
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCSaxenda (liraglutide) is not FDA-approved for alcohol use disorder, and any use for this condition is off-label or investigational. Research in animals suggests liraglutide may reduce alcohol consumption and related effects, but these findings have not been confirmed in humans.
AI summary of the sources below.
| Drug | Saxenda (liraglutide) |
|---|---|
| Condition | Alcohol use disorder |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Saxenda is not FDA-approved for alcohol use disorder; the research below reflects investigational or off-label study only.
Research on liraglutide for alcohol use disorder (5)
- The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.
- Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
- Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice.
- Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.
- A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.